KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Charles River Laboratories International (CRL) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $253.8 million.

  • Charles River Laboratories International's Long-Term Debt Repayments fell 2301.01% to $253.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 1950.7%. This contributed to the annual value of $1.5 billion for FY2024, which is 7539.17% up from last year.
  • Latest data reveals that Charles River Laboratories International reported Long-Term Debt Repayments of $253.8 million as of Q3 2025, which was down 2301.01% from $738.3 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Long-Term Debt Repayments registered a high of $2.5 billion during Q2 2021, and its lowest value of $149.4 million during Q1 2025.
  • Its 5-year average for Long-Term Debt Repayments is $666.4 million, with a median of $408.2 million in 2022.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first surged by 200410.49% in 2021, then crashed by 8340.89% in 2023.
  • Over the past 5 years, Charles River Laboratories International's Long-Term Debt Repayments (Quarter) stood at $1.1 billion in 2021, then crashed by 61.21% to $408.2 million in 2022, then decreased by 21.43% to $320.8 million in 2023, then tumbled by 44.89% to $176.8 million in 2024, then skyrocketed by 43.57% to $253.8 million in 2025.
  • Its last three reported values are $253.8 million in Q3 2025, $738.3 million for Q2 2025, and $149.4 million during Q1 2025.